Unknown

Dataset Information

0

Serum microRNA-155 as a potential biomarker to track disease in breast cancer.


ABSTRACT: BACKGROUND: One major impediment to improving the management of breast cancer is the current lack of tumor marker with sufficient sensitivity and specificity. A growing body of evidence implicates the diagnostic potential of circulating miRNAs in cancer detection. MiR-155 plays an important role in the pathogenesis of breast cancer. However, the level of circulating miR-155 and its clinical relevance are not well established. The objective of the current study was to learn more about serum miR-155 in patients with breast cancer. METHODOLOGY/PRINCIPAL FINDINGS: Using quantitative reverse transcription polymerase chain reaction (RT-qPCR), we demonstrated that serum miR-155 had significant increased levels in breast cancer patients (n?=?103) compared with healthy subjects (n?=?55) (p<0.001), which had a mean fold change of 2.94. Receiver operating characteristic (ROC) analysis revealed that miR-155 had considerable diagnostic accuracy, yielding an ROC-AUC (the areas under the ROC curve) of 0.801 (sensitivity 65.0%, specificity 81.8%). In addition, sera from a subset of breast cancer patients (n?=?29) were collected after surgery and after four cycles of chemotherapy to evaluate the effects of clinical treatment on serum levels of candidate miRNAs. Surprisingly, a decreased level of serum miR-155 was found; whereas the concentrations of carbohydrate antigen 15-3 (CA15-3), carcinoembryonic antigen (CEA) and tissue polypeptide specific antigen (TPS) did not show this trend. Our results revealed that 79% patients showed response or stable disease after therapy had declined levels of serum miR-155. CONCLUSIONS/SIGNIFICANCE: Our results suggest that serum miR-155 is a potential biomarker to discriminate breast cancer patients from healthy subjects. For the first time, we demonstrated a declined trend of miR-155 after surgery and chemotherapy, which raises the possibility to use it as an indicator for treatment response.

SUBMITTER: Sun Y 

PROVIDER: S-EPMC3468565 | BioStudies | 2012-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC6930394 | BioStudies
2009-01-01 | S-EPMC3743675 | BioStudies
2015-01-01 | S-EPMC4514648 | BioStudies
2018-01-01 | S-EPMC5976482 | BioStudies
2020-01-01 | S-EPMC7495225 | BioStudies
2016-01-01 | S-EPMC4999206 | BioStudies
2018-01-01 | S-EPMC5935014 | BioStudies
2018-01-01 | S-EPMC5954898 | BioStudies
1000-01-01 | S-EPMC5809836 | BioStudies
2019-01-01 | S-EPMC6390256 | BioStudies